My 2nd derivative trade worked out $EVK (+1.4%) . The war in the Gulf and the outages have led to a severe shortage of methionine. $EVK (+1.4%) Barclays holds 45% of its share outside Asia and can therefore guarantee security of supply for Europe and the USA. Barclays expects an uplift in EBITDA of € 580 million in 2026 due to the higher price level.

Where are the highest dividends expected to be paid in Germany in 2026?

The editors of "Welt | Alles auf Aktien" have looked into the question. Here is an excerpt:

Overall, the total dividend payout in Dax and MDax will probably decline overall in 2026. One of the main reasons for this is the weak earnings performance in the automotive industry, which is an important dividend payer.

The amounts that German companies will pay out in 2026 have only been determined in a few cases.

The highest payout in 2026 can be expected from the RTL Group
$RTLL (+1.25%) can be expected. According to analysts, shareholders of the media group can expect a credit of 3.19 euros per share next year, which corresponds to a yield of 9.6 percent based on the current share price. This does not yet include the expected five-euro special dividend resulting from the sale of RTL Nederland. Incidentally, RTL was already one of the top dividend payers this year, with an additional 23 percent share price gain.

Shareholders of Evonik Industries $EVK (+1.4%) can also hope for more than nine percent. The Essen-based company is so stable in its niches that it has been able to maintain its dividend at EUR 1.17 for four years. Overall, they are the market leader in 20 different areas. In 2026, too, there will be 1.17 euros per share, which would be a current yield of 9.1 percent at the current share price.

Another dividend pearl is Freenet $FNTN (-1.56%). The mobile operator is a favorite of dividend collectors. Experts say it will probably pay 2.10 euros per share in 2026. That would be 7.5 percent. This year, the share price has risen slightly in addition to the generous dividend.

The same cannot be said for the next dividend share: Ströer $SAX (+0.38%). Not only did the operator of outdoor and online advertising lose a lot in 2025, the share price has not budged for ten years. In this case, the dividend yield of 6.3 percent is little consolation.

The last dividend pearl is BASF $BAS (+1%). The company was once the largest chemical group in the world, but here too - if you look at the share price - there has been no progress and no growth for more than ten years. At least the Ludwigshafen-based company will be able to keep its dividend stable in 2026, according to analysts. That would be 2.25 euros per share, or a good five percent current yield.

Source text and image, "Welt", 09.12.25

November was once again a classic "rollercoaster month" - with a fortunately positive outcome. We started with a portfolio performance of -3% and then rose to +5% in the middle, then fell again to -2% and closed the month with around +8%! For the portfolio, this means that we have reached a new all-time high! 👍🏼

Start: 1,148,200 euros

End: 1,253,497 euros + 19,000 cash

Deposit: 30,000 euros

Profit: +94,297 euros (+8.2%)

Once again this month (as in October), my two gold positions were mainly responsible for the volatility, as they now account for 44% of my portfolio - but hey, I'm still convinced that there's a lot of potential in these stocks. So the rollercoaster will continue... 🎢

One of my less heavily weighted mining stocks, $SCZ (+2.54%) SantaCruz Silver Mining, I sold completely on Friday after disappointing quarterly figures. Although the share is being driven by the strong silver price, this can quickly go in the other direction if the support falls away. The bottom line was a gain of +12% after only 6 weeks. We can be satisfied with that. I only have a total of 4 mines left in my portfolio: $KNT (+0.84%)
$EQX (+0.57%)
$BTO (+1.12%) and $ESM (+0.21%) .

Otherwise, I used the month to buy stocks that had fallen out of favor but that I am still convinced of. These include $PYPL (-0.49%)
$NOVO B (+1.61%)
$1810 (+3.55%) (Xiaomi) $GLJ (+0.92%) (Grenke), $LXS (+4%) and $EVK (+1.4%) have been. Novo-Nordirsk in particular presented a great opportunity a few days ago when the share price briefly plummeted by 10% without justification. 📉

At the same time, I was also able to realize a few profits. I took the opportunity to sell some of my Puma shares after the takeover rumors and at the beginning of the month I also sold Lufthansa, BHP Billiton and a small amount of Western Union (which has already been bought back at a lower price). 📈

I currently hold 19,000 euros in cash again and am waiting for the next opportunities! 💵

➡️🆓: On my way towards 4 million total assets, the target achievement rate is now 42.3%. 😊

Let's see how November turns out. As always, it remains exciting!

Since September 1999, Bankhaus Metzler has published a list of ten German shares that it recommends for the following quarter. Since then, this top ten list has achieved a return of more than 600 percent. In the same period, Germany's leading index, the Dax, gained around 350 percent.

The research team has now published the top 10 for the third quarter.

• 4 DAX stocks

$DB1 (+0.14%)
$MUV2 (-0.48%)
$SIE (+0.22%)

• 3 MDAX stocks

$BC8 (+2.1%)
$EVK (+1.4%)
$JUN3 (+0.69%)

• 2 SDAX stocks

$BFSA (+0.36%)
$VOS (+1.14%)

• 1 stock outside the indices

$IVU (-0.96%)

Source: Handelsblatt, 04.07.25

$EVK (+1.4%) is unfortunately not at its best at the moment, like so many other companies.

Personally, however, I have to say that I am quite optimistic about Evonik's future. I think the restructuring and reallocation of investments that Evonik is currently planning and already implementing is a good opportunity to become one of the top chemical companies in a few years' time. In a world where the demand for resources is pushing the limits every year, a company that focuses on sustainable product development is a goldmine.

With a little good leadership and confidence in the plan, Evonik can turn the tide. Nevertheless, one should not count one's chickens before they hatch. Evonik still has a long way to go and a lot can still happen. I will keep an eye on the share and base my decisions on my observations. That's my opinion, let me know what you think.

Hope for US-Chinese rapprochement lives on + Secret revealed: Trump wants to cut drug prices + Evonik confirms annual target + Formycon starts the year with losses

Hope for US-Chinese rapprochement lives on

• Progress in the tariff conflict between the USA and China should ensure a positive mood on Europe's stock markets on Monday.
• The Dax is likely to continue its record-breaking run, which it resumed on Friday after a break of almost two months.
• Wall Street is also expected to be strong, while the start of the week in Asia was rather subdued.
• According to the White House, the USA has reached an agreement with China on the tariff dispute during talks in Geneva.
• No details were initially given. Both sides announced a statement for Monday.
• The Chinese delegation initially only spoke of a "series of important agreements".

Secret revealed: Trump wants to lower prices for medicines

• The big announcement made by US President Donald Trump is now out:
• He wants to lower the prices of prescription drugs and is taking aim at the pharmaceutical industry.
• He will sign one of the "most consequential decrees" in US history on Monday morning (local time), the Republican announced on his online mouthpiece Truth Social.
• He had previously written there that he would be making "one of the most important" announcements ever.
• Trump had already held out the prospect of an "earth-shattering" announcement last week.
• US media had already speculated that it could be about drug prices.
• Drug prices are an important issue in the USA.
• There is currently no central government price regulation that applies to all medicines.
• The pharmaceutical industry plays the most important role in the question of how much a drug costs - government influence is limited.
• This sometimes leads to enormously high prices - in an international comparison, many medicines in the USA are significantly more expensive.
• In Germany, on the other hand, various forms of state regulation take effect.
• Trump promises significant price reduction Trump sees the USA at a disadvantage because of the high prices.
• The world wonders why prescription drugs are so much more expensive in the USA than in other countries around the world, even though they are produced in the same laboratory by the same company, he wrote.
• "It was always hard to explain and very embarrassing because, in truth, there was no real or justifiable explanation." Trump promised that drug prices in the US would fall by 30 to 80 percent "almost immediately".
• "Worldwide, prices will rise to create balance and - for the first time in many years - bring justice to America!"
• Trump wants to ensure that no more is paid for certain prescription drugs in the USA than in other countries.
• It remains to be seen whether this only applies to drugs covered by the state health insurance program for senior citizens (Medicare) - or whether Trump wants to go one step further with price regulation.
• This could be particularly difficult legally - but pharmaceutical companies are likely to oppose the plan anyway.
• Trump's idea is not new Trump wants to tackle high prices with the "Most Favored Nation" system.
• He had already pushed this unsuccessfully during his first term in office.
• The idea is to link the reimbursement prices for medicines to the lowest price in wealthy comparator countries in order to reduce the high cost of medicines in the USA.
• This would force pharmaceutical companies to accept internationally comparable prices.
• The proposal was never implemented; there was legal and political resistance.
• In Trump's announcement, it now sounded as if it was not just about comparable prices in certain countries.
• Trump wrote that the USA would pay the same price as the country that pays the lowest price for a drug worldwide.
• Trump went on to emphasize: "Campaign contributions can work wonders - but not for me and not for the Republican Party."
• His government will now do the right thing - something the Democrats have been fighting for for years.
• The regulation of drugs was one of the central issues of Trump's predecessor in office, Joe Biden.
• Biden signed a major legislative package in 2022 that also authorized Medicare to negotiate certain drug prices.
• Biden's measure was considered a milestone.

Evonik $EVK (+1.4%)confirms annual target - operating profit recovers at the start of the year

• Better business with animal feed protein and continued cost-cutting efforts helped Evonik to increase profits in the first quarter.
• In addition, business with products for the paints and coatings industry and with active pharmaceutical ingredients improved.
• The annual profit target has been set. With sales almost unchanged at just under €3.8 billion, earnings before interest, taxes, depreciation and amortization (EBITDA) adjusted for special items rose by 7 percent year-on-year to €560 million, as the MDax-listed company announced on Monday.
• This is slightly less than analysts expected in terms of turnover, but more in terms of profit.
• The bottom line was 233 million euros, compared to 156 million a year ago.
• "Our efficiency efforts are taking effect.
• And this is also urgently needed in view of the renewed economic concerns," says CFO Maike Schuh.
• She and Evonik CEO Christian Kullmann are still targeting an operating profit (EBITDA) of between €2.0 billion and €2.3 billion for the current year, following a significant recovery to almost €2.07 billion in 2024.

Biotech company Formycon $FYB (-1.57%)starts the year with losses

• A decline in milestone payments and reimbursements for development services weighed on biosimilar manufacturer Formycon at the start of the year.
• However, neither is surprising, as projects are progressing.
• In addition, there is partial price pressure on sales in the USA.
• According to a statement on Monday, turnover in the first quarter fell by 70 percent year-on-year to EUR 5.3 million.
• Earnings before interest, taxes, depreciation and amortization (EBITDA) slipped from minus 5.5 to minus 13.2 million euros.
• The company confirmed its forecast for the current year.

Monday: Stock market dates, economic data, quarterly figures

Singapore stock exchange holiday

• ex-dividend of individual stocks
• Villeroy & Boch AG ex dividend € 0.90
• Draegerwerk AG & Co KGaA ex dividend € 2.03
• Draegerwerk AG & Co KGaA € 1.97
• DMG Mori AG € 1.03

• Quarterly figures / Company dates USA / Asia
• 07:00 Mazda quarterly figures
• 14:00 Fox Corp Quarterly figures

• Quarterly figures / Company dates Europe
• 07:00 Evonik Industries | Unicredit | Procredit | Formycon Quarterly figures
• 07:10 Hypoport quarterly figures
• 07:30 Salzgitter | Adesso | United Internet Quarterly figures
• 07:50 1&1 Quarterly figures
• 09:00 Ionos quarterly figures | Salzgitter analyst conference
• 10:00 Siltronic AGM
• 11:00 Evonik Analyst Conference
• 12:00 United Internet Analyst Conference
• 14:00 Hochtief quarterly figures
• 15:00 Formycon Conference Call

• Economic data

08:00 DE: Domestic Tourism March

15:00 EU: Eurogroup meeting

The German bank has now also used the coalition agreement and the associated special fund as the basis for a list of recommendations.

The result is a list of 10 potential profiteers.

The result:

$CBK (+0.28%) - Commerzbank

$ENR (-0.69%) - Siemens Energy

$VOS (+1.14%) - Vossloh

$HEI (+1.22%) - Heidelberg Materials

$EVK (+1.4%) - Evonik

$KGX (+0.92%) - Kion

$BC8 (+2.1%) - Bechtle

$COK (+2.35%) - Cancom

$VOW (-0.32%) - Volkswagen

$PAL (-1.55%) - Palfinger

Source: "Welt"

I was inspired by a Focus Money article and because many people here are asking.

I won't be investing myself, it's too short-term for me. But there are still some very interesting companies.

Feel free to write in the comments whether such "copied articles" are of any use to the community or are legally correct :)

The signs of a peace process in Ukraine are solidifying. This is triggering a run on the stock market for shares that could benefit from reconstruction

Regardless of the political interpretation, the stock market has been turning its back on the war for several days now and is betting on the coming peace. Stocks that are likely to benefit from the reconstruction in Ukraine have soared. The UBS Ukraine Reconstruction Index, which comprises 25 of these stocks, has been climbing for days and is at an all-time high. "The effects of a possible ceasefire in Ukraine are still being underestimated on the financial markets," says Bernd Meyer, Chief Investment Strategist and Head of Multi Asset at Berenberg, who is convinced that the rally will continue. Reconstruction requires enormous resources. According to estimates by the World Bank, the costs for this amount to a total of 500 billion dollars - the equivalent of Austria's gross domestic product and more than three times Ukraine's annual economic output before the war. The money is likely to benefit construction companies, suppliers, infrastructure companies and banks in particular. European companies could be the main beneficiaries - especially from neighboring countries such as Poland and Hungary, but also the Czech Republic, Austria and Germany.

With Wärtsilä $WRT1V (-0.98%) a provider of technologies for the shipping and energy markets, and Konecranes $KCR (+0.2%) a manufacturer of industrial cranes and drive technology, Finnish companies are also on the list of potential peace beneficiaries - as are Italian companies such as the cement and building materials manufacturer Buzzi $BZU (-0.02%) The list is long. There is a great need for building materials, steel and cables to restore the destroyed infrastructure and energy supply. There is still no thematic fund or ETF on the beneficiaries of the reconstruction in Ukraine. Investors who want to benefit from this are therefore well advised to combine several securities into a portfolio themselves.

Banks: Erste Group Bank $EBS (-0.09%) Powszechna K. Osz $PKO (-1.37%) Santander Polska $SPL (-0.57%) Polska K. Opieki $PEO (-1.02%) Raiffeisen Bank Int.$RBI (+1.11%)

Construction: Wienerberger $WIE (+0.4%) Sniezka Construction $SKA Strabag $STR (-0.11%)

Insulation: Kingspan Group $KRX (-0.16%) Rockwool $ROCK B

Glass: Cie de Saint-Gobain $SGO (+1.72%)

Cranes: Konecranes $KCR (+0.2%)

Cement: CRH $CRH (-1.06%) Buzzi $BZU (-0.02%) Holcim $HOLN (-0.05%) Heidelberg Mat. $HEI (+1.22%)

Construction machinery: Caterpillar $CAT (+0.17%)

Mining: Ferrexpo $FXPO (+0.75%) Metso $METSO (+0.12%)

Chemicals: BASF $BAS (+1%)

Industrial gases: Air Liquide $AI (+0.43%)

Infrastructure: Schneider Electric $SU (+0.27%) Rexel $RXL (+1.56%) Wärtsilä $WRT1V (-0.98%) Weir Group $WEIR (+0.56%)

Infrastructure (E): Siemens Energy $ENR (-0.69%) Prysmian $PRY (+0.93%) NKT $NKT (-0.55%) Nexans $NEX (+0.74%)

Agriculture: Kernel $KER (+0.37%)

Logistics(warehouse): Kion $KGX (+0.92%)

Steel: Arcelor Mittal $MT (+0.17%) and for stainless steels Outukompu $OUT1V (+1.89%)

Sanitary technology: Geberit $GEBN (+0.36%)

Specialty chemicals: Evonik $EVK (+1.4%) Arkema $AKE (+2.54%) Wacker Chemie $WCH (+3.82%) Lanxess $LXS (+4%)

⬆️⬆️⬆️

- BERNSTEIN raises the price target for MOLLER-MAERSK from DKK 9650 to DKK 9700. Underperform. $AMKBY (-0.94%)

⬇️⬇️⬇️

-JPM Securities downgrading $GOOGL (+0.52%)

-JPM Securities downgrading $UBER (+0.92%)

- BERENBERG lowers the price target for EVONIK from EUR 20 to EUR 18. Hold. $EVK (+1.4%)

- BERNSTEIN lowers the target price for DHL GROUP from EUR 42.50 to EUR 41. Outperform. $DHL (-0.07%)

- JEFFERIES lowers the target price for LINDE from USD 550 to USD 522. Buy. $LIN (+0.29%)

- $SOFI (+2.18%) Keefe, Bruyette & Woods Downgrades to Underperform PT to $7 from $8

-UBS starting the year again with some negative data for $AAPL (+0.09%) naming China an issues

The existing position is reduced in price.